**Reporting Summary**

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

### Statistical parameters

When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).

| n/a | Confirmed |
|-----|-----------|
|     |           |

- The exact sample size ($n$) for each experimental group/condition, given as a discrete number and unit of measurement
- An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
- Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. $F$, $t$, $r$) with confidence intervals, effect sizes, degrees of freedom and $P$ value noted.
- Give $P$ values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen’s $d$, Pearson’s $r$), indicating how they were calculated
- Clearly defined error bars
- State explicitly what error bars represent (e.g. SD, SE, CI)

Our web collection on statistics for biologists may be useful.

### Software and code

Policy information about availability of computer code

**Data collection**  
No software was used

**Data analysis**  
Graph pad version 6. Fiji ImageJ 1.51n. Imaris version 8.1.2

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

### Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

All data generated or analysed during this study are included in this published article (and its supplementary information files). All other relevant data are available from the authors upon reasonable request.
Field-specific reporting

Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences  - Behavioural & social sciences  - Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/authors/policies/ReportingSummary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Sample size | We analyzed high n numbers for dendritic spine analysis and whole organism experiments yielding high significance underscoring the robustness of our analysis. Standard n numbers were used for biochemical analysis. |
| Data exclusions | No data were excluded from the analysis. |
| Replication | Neurons were imaged from 3 separate primary culture preparations. Viable neurons for each experimental group were detected by the analysis software based on the MAP2 signal. Nematode analyses were performed in triplicates at different times to take into account any possible variations between the cohorts. |
| Randomization | Images of viable neurons and images of nematodes from all experimental groups were randomly taken. For the lifespan and fecundity assays, nematodes were randomly chosen by picking the indicated number of nematode larvae and all animals were then analyzed. No further selection of data subsets was applied. |
| Blinding | Image collection and analysis were performed by separate investigators. Blinded analysis was ensured by using a predefined software routine with constant parameters. |

Reporting for specific materials, systems and methods

Materials & experimental systems

| Materials & experimental systems | n/a | Involved in the study |
| --- | --- | --- |
| Unique biological materials | | |
| Antibodies | | |
| Eukaryotic cell lines | | |
| Palaeontology | | |
| Animals and other organisms | | |
| Human research participants | | |

Methods

| Methods | n/a | Involved in the study |
| --- | --- | --- |
| ChIP-seq | | |
| Flow cytometry | | |
| MRI-based neuroimaging | | |

Unique biological materials

Policy information about availability of materials

Obtaining unique materials

Describe any restrictions on the availability of unique materials OR confirm that all unique materials used are readily available from the authors or from standard commercial sources (and specify these sources).

Antibodies

Antibodies used

- Anti-DBN M2F6 (1:1000 for western blot, 1:100 for immunohistochemistry, ADI-NBA-110-E Enzo), anti-ATM 2C1(1A1) (1:200, ab78 ABCAM), anti-pS1981-ATM 10H11.E12 (1:400, 200-301-4005, Rockland), anti-p-p44-42 ERK (pMAPK, 1:1000 #9101 CST), anti-a-Tubulin (1:5000, T6199, Sigma), anti-pGAPDH (1:5000, CB1001 MERCK), anti-pS15-p53 (1:1000 #9284, CST), anti poly-mono ubiquitin FK2 (1:1000, BML-PW8810 Enzo), anti-alpha 3F10 (1:1000, ab78 ABCAM), anti-ATM 2C1(1A1) (1:200, ab78 ABCAM), anti-DBN-1 C. elegans specific (1:500), anti-Biotin mouse (1:5000, B7653 Sigma) or anti-Biotin rabbit (1:5000, #5597 Cell signalling). The most important uncropped western blots are included in the Supplementary information.

Validation

For Western blotting, anti-Drebrin and anti-ATM Antibodies were validated using Dbn+/+ and Dbn -/- as well as Atm +/- and Atm
- Brain or neuronal lysates (data supplied in the manuscript). PS647-DBN specific antibodies were validated using DBN-YFP phospho-mutants or phosphatase assays (Kreis et al., 2013). Other antibodies such as alpha-tubulin or pMAPK were commonly used antibodies and ran at the expected size. For immunostaining, anti-Drebrin antibodies were also validated using Dbn+/+ and Dbn-/- primary hippocampal cultures.

### Eukaryotic cell lines

**Policy information about** [cell lines](#)

| Cell line source(s) | HEK293T (ATCC, CRL-11268) and COS-7 (ATCC, CRL-1651) |
|---------------------|--------------------------------------------------------|
| Authentication      | Cell line commercially acquired                        |
| Mycoplasma contamination | All cell lines tested negative for mycoplasma contamination |
| Commonly misidentified lines (See ICLAC register) | Name any commonly misidentified cell lines used in the study and provide a rationale for their use. |

### Palaeontology

**Specimen provenance**

Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).

**Specimen deposition**

Indicate where the specimens have been deposited to permit free access by other researchers.

**Dating methods**

If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.

Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

### Animals and other organisms

**Policy information about** [studies involving animals](#), [ARRIVE guidelines](#) **recommended for reporting animal research**

**Laboratory animals**

Mice:
- Adult pregnant female mice: C57BL/6N
- Hippocampi were dissected from E16.5 male and female embryos

Rat:
- Wistar P0-P1 male and female were used for primary neuronal cultures. Other developmental stages E15, E17, E19, P1, P7, P15, P21, week 10, week 20, week 30, week 40 both male and female were used for protein analysis.

**Wild animals**

Provide details on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.

**Field-collected samples**

For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.

### Human research participants

**Policy information about** [studies involving human research participants](#)

**Population characteristics**

Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write “See above.”

**Recruitment**

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

### ChIP-seq

**Data deposition**

- Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).
- Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

**Data access links**

For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.

May remain private before publication.
### Experimental design

#### Design type

- Indicate task or resting state; event-related or block design.

#### Design specifications

- Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.

#### Behavioral performance measures

- State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).

### Magnetic resonance imaging

#### Methodology

- **Replicates**: Describe the experimental replicates, specifying number, type and replicate agreement.
- **Sequencing depth**: Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.
- **Antibodies**: Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.
- **Peak calling parameters**: Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.
- **Data quality**: Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.
- **Software**: Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.

### Flow Cytometry

#### Plots

- Confirm that:
  - The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
  - The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a ‘group’ is an analysis of identical markers).
  - All plots are contour plots with outliers or pseudocolor plots.
  - A numerical value for number of cells or percentage (with statistics) is provided.

#### Methodology

- **Sample preparation**: Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.
- **Instrument**: Identify the instrument used for data collection, specifying make and model number.
- **Software**: Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a community repository, provide accession details.
- **Cell population abundance**: Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined.
- **Gating strategy**: Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between “positive” and “negative” staining cell populations are defined.

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

### Genome browser session

- **Files in database submission**: Provide a list of all files available in the database submission.
- **Genome browser session (e.g. UCSC)**: Provide a link to an anonymized genome browser session for “Initial submission” and “Revised version” documents only, to enable peer review. Write “no longer applicable” for “Final submission” documents.

### Methodology

- **Replicates**: Describe the experimental replicates, specifying number, type and replicate agreement.
- **Sequencing depth**: Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.
- **Antibodies**: Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.
- **Peak calling parameters**: Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.
- **Data quality**: Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.
- **Software**: Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.

### Flow Cytometry

#### Plots

- Confirm that:
  - The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
  - The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a ‘group’ is an analysis of identical markers).
  - All plots are contour plots with outliers or pseudocolor plots.
  - A numerical value for number of cells or percentage (with statistics) is provided.

#### Methodology

- **Sample preparation**: Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.
- **Instrument**: Identify the instrument used for data collection, specifying make and model number.
- **Software**: Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a community repository, provide accession details.
- **Cell population abundance**: Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined.
- **Gating strategy**: Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between “positive” and “negative” staining cell populations are defined.

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

### Magnetic resonance imaging

#### Experimental design

- **Design type**: Indicate task or resting state; event-related or block design.
- **Design specifications**: Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.
- **Behavioral performance measures**: State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).
### Acquisition

**Imaging type(s)**
Specify: functional, structural, diffusion, perfusion.

**Field strength**
Specify in Tesla

**Sequence & imaging parameters**
Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.

**Area of acquisition**
State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.

**Diffusion MRI**
[ ] Used  [ ] Not used

### Preprocessing

**Preprocessing software**
Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).

**Normalization**
If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.

**Normalization template**
Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.

**Noise and artifact removal**
Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).

**Volume censoring**
Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.

### Statistical modeling & inference

**Model type and settings**
Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).

**Effect(s) tested**
Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.

Specify type of analysis:  [ ] Whole brain  [ ] ROI-based  [ ] Both

**Statistic type for inference**
Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods. (See Eklund et al. 2016)

### Models & analysis

**Involved in the study**

| [ ] Functional and/or effective connectivity |
| [ ] Graph analysis |
| [ ] Multivariate modeling or predictive analysis |

**Functional and/or effective connectivity**
Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).

**Graph analysis**
Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).

**Multivariate modeling and predictive analysis**
Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.